Beijing Fulong Kangtai Biotechnology

Beijing Fulong Kangtai Biotechnology is a biopharmaceutical company based in Beijing, China, focused on the development and commercialization of high-end vaccines and biological products. The company's flagship program is a human diploid cell rabies vaccine, which is currently in late-stage clinical development and represents a significant advancement in vaccine safety and efficacy compared to traditional animal cell-derived vaccines. Fulong Kangtai maintains a robust R&D infrastructure and a large-scale GMP-compliant manufacturing base in the Beijing Economic-Technological Development Area. Beyond vaccines, the company explores recombinant protein technologies for various therapeutic applications. Its mission is to address critical public health needs through innovative biotechnology solutions.